The successful treatment of 6 cases of lentigo maligna (LM) with topical imiquimod was recently reported by Wolf et al.1 We describe a 78-year-old woman with an extensive recurrent LM (melanoma in situ) that completely regressed after 12 weeks of topical imiquimod therapy. Dermoscopic analysis was useful to confirm the initial diagnosis and to monitor treatment efficacy.
The recently described dermoscopic features of facial LM have proved crucial to differentiate LM from solar lentigo (lentigo senilis), seborrheic keratosis, lichen planus–like keratosis, and pigmented actinic keratosis.2 Characteristic dermoscopic features of early-phase LM are asymmetrical pigmented follicular openings, slate-gray dots and globules aggregated around hair follicles, and short brown or black streaks. Disease progression is characterized by the appearance of long and intersected streaks that form rhomboidal structures around the follicles, clearly visible annular-granular structures due to the confluence of dots and globules, and homogeneous areas.2 Dermoscopy has been also shown to enhance the diagnostic accuracy of determining the clinical borders of LM lesions and to guide the margin of resection.3
Clinical appearance of lentigo maligna before (A) and after (B) 12 weeks of 5% imiquimod therapy.
Dermoscopic images obtained before and after 6 and 12 weeks of treatment with 5% imiquimod. A, Before treatment, asymmetrical pigmented follicular openings (arrowhead) and annular-granular (white arrow) and rhomboidal (black arrow) structures are clearly visible around the follicular openings. B, After 6 weeks of treatment, a reduction of the annular-granular and rhomboidal structures is observed. C, After 12 weeks of treatment, there is a complete absence of the dermoscopic structures that are characteristic of lentigo maligna.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 11
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.